Charles River (NYSE:CRL) Upgrade

Barclays raised shares of Charles River (NYSE:CRL) from a Underweight rating to a Equal Weight rating in a analysts report released on Wednesday morning. The firm now has $77.0 PT on the stock.

Charles River Laboratories Intl. Inc (NYSE:CRL) Ratings Coverage

Out of 10 analysts covering Charles River Laboratories (NYSE:CRL), 4 rate it a “Buy”, 3 “Sell”, while 3 “Hold”. This means 40% are positive. $100 is the highest target while $65 is the lowest. The $82.88 average target is 16.63% above today’s ($71.06) stock price. Charles River Laboratories has been the topic of 18 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The stock of Charles River Laboratories Intl. Inc (NYSE:CRL) earned “Outperform” rating by William Blair on Friday, August 28. The firm has “Neutral” rating by Credit Suisse given on Tuesday, June 21. Wells Fargo upgraded the stock to “Outperform” rating in Thursday, January 7 report. As per Thursday, August 4, the company rating was maintained by Citigroup. The rating was maintained by Jefferies with “Buy” on Thursday, August 4. The stock has “Market Perform” rating given by Wells Fargo on Monday, October 12. UBS downgraded Charles River Laboratories Intl. Inc (NYSE:CRL) on Tuesday, September 6 to “Sell” rating. Credit Suisse reinitiated Charles River Laboratories Intl. Inc (NYSE:CRL) rating on Friday, August 14. Credit Suisse has “Neutral” rating and $84 price target. Jefferies maintained the stock with “Buy” rating in Friday, January 8 report. Barclays Capital maintained Charles River Laboratories Intl. Inc (NYSE:CRL) on Friday, May 20 with “Underweight” rating.

About 442,247 shares traded hands. Charles River Laboratories Intl. Inc (NYSE:CRL) has declined 12.23% since April 27, 2016 and is downtrending. It has underperformed by 17.46% the S&P500.

Analysts await Charles River Laboratories Intl. Inc (NYSE:CRL) to report earnings on February, 8. They expect $1.12 earnings per share, up 12.00% or $0.12 from last year’s $1 per share. CRL’s profit will be $52.96 million for 15.86 P/E if the $1.12 EPS becomes a reality. After $1.18 actual earnings per share reported by Charles River Laboratories Intl. Inc for the previous quarter, Wall Street now forecasts -5.08% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 0.95 in 2016 Q2. Its down 0.48, from 1.43 in 2016Q1. The ratio is negative, as 25 funds sold all Charles River Laboratories Intl. Inc shares owned while 81 reduced positions. 39 funds bought stakes while 113 increased positions. They now own 44.08 million shares or 4.37% less from 46.09 million shares in 2016Q1.

Pembroke last reported 2.39% of its portfolio in the stock. Winfield Associate, a Ohio-based fund reported 10 shares. Acadian Asset Limited Liability Company has 1.73 million shares for 0.73% of their US portfolio. Ameritas Invest, a Nebraska-based fund reported 7,460 shares. Bokf Na reported 22,260 shares or 0.06% of all its holdings. Jpmorgan Chase Communications holds 181,186 shares or 0% of its portfolio. Aristotle Capital Boston Limited Liability has 48,975 shares for 0.91% of their US portfolio. Ariel Limited Liability holds 1.52% or 1.46 million shares in its portfolio. Healthinvest Prtnrs Ab reported 149,612 shares or 5.66% of all its holdings. Liberty Mutual Group Asset holds 20,281 shares or 0.06% of its portfolio. State Of New Jersey Common Pension Fund D owns 35,000 shares or 0.01% of their US portfolio. Suntrust Banks last reported 5,794 shares in the company. Aqr Management Ltd Llc holds 0.16% or 1.11 million shares in its portfolio. The New York-based Laurion Cap Ltd Partnership has invested 0% in Charles River Laboratories Intl. Inc (NYSE:CRL). Advantus Capital Mgmt has 5,713 shares for 0.01% of their US portfolio.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 7 selling transactions for $4.75 million net activity. FOSTER JAMES C had sold 18,351 shares worth $1.57 million. $326,485 worth of Charles River Laboratories Intl. Inc (NYSE:CRL) was sold by REESE C RICHARD. 3,740 Charles River Laboratories Intl. Inc (NYSE:CRL) shares with value of $310,750 were sold by MASSARO GEORGE. WALLMAN RICHARD F had sold 7,740 shares worth $681,120 on Friday, July 29. 7,877 shares with value of $662,446 were sold by Molho Davide on Tuesday, August 30.

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The company has a market cap of $3.36 billion. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. It has a 23.85 P/E ratio. The Firm operates through three divisions: Research Models and Services , which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

According to Zacks Investment Research, “Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years.”

CRL Company Profile

Charles River Laboratories International, Inc., incorporated on February 3, 1994, is a full service, early-stage contract research company. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Firm operates through three divisions: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development. It also provides a suite of services and products to support its clients’ manufacturing activities.

Another recent and important Charles River Laboratories Intl. Inc (NYSE:CRL) news was published by Benzinga.com which published an article titled: “Benzinga’s Top Upgrades” on November 30, 2016.